

March 2023 PDL/DUR Board Meeting Minutes

Date: March 15, 2023

Members Present: Barnhill, Blake, Blank, Brown, Caldwell, Jost, McGrane, Nauts, Stone, Turnsplenty

Members Absent: Anglim, Putsch

Others Present: Shannon Sexauer, Dani Feist (DPHHS); Kathy Novak (Magellan); Bahny, Miranda, Zody (MPQH); and representatives from the pharmaceutical industry.

Public Comment: Speaker information is as follows:

- Kimberly Simpson, United Therapeutics Corporation - Tyvaso®/Tyvaso® DPI
- Arlene Mejia, Pierre Fabre - Hemangeol®
- Jein Song, Xeris Pharma – Gvoke HypoPen®
- Shirley Quach, Novartis - Entresto®
- David Chapman, Myovant Sciences - Myfembree®
- Nirmal Ghuman, Janssen Scientific Affairs - Opsumit®
- Carrie Johnson, Amgen - Repatha®
- Uche Mordi, Bristol Myers Squibb - Zeposia®

Meeting Minutes Review: Minutes from the February 2023 DUR Board meeting were not available for review during this meeting but will be available for review at the April 26, 2023 PDL meeting.

Department Update: DPHHS will be posting provider notices, some specific to each program, in the coming weeks regarding the unwinding of the Public Health Emergency (PHE). These notices will provide guidance on which PHE flexibilities are being discontinued and the effective date of those discontinuations. MT DPHHS urges all Medicaid providers to be on the lookout for these notices and ensure they read them and understand what is to come. If there are any questions regarding these notices, please feel free to reach out to the respected DPHHS program staff for assistance.

PREFERRED DRUG LIST MEETING

Results of the Board review of Group 3 (**Red category**):

CLASS	DRUGS Reviewed	2023 RECOMMENDATIONS	Grandfather
BONE RESORPTION SUPPRESSION & RELATED AGENTS	NI-Tymlos®	<u>Nasal Calcitonins</u> : Class effect with existing PA criteria. <u>Bisphosphonates & Bone Resorption</u> . Others: Class effect.	NO
COLONY STIMULATING FACTORS	ND-Fylnetra® Releuko®, Rolvedon®, Stimufend® NI-Udenyca®	Therapeutic alternatives. Must have one filgrastim like agent and one pegfilgrastim like agent.	NO
GI MOTILITY, CHRONIC	ND-Ibsrela®,	Therapeutic alternatives for each of the following categories: OIC: Movantik®, Relistor®, Amitiza®, Symproic® IBS-D: Alosetron®, Viberzi® IBS-C/CIC: Amitiza®, Linzess®, Trulance®, Motegrity®, <i>add Ibsrela® (IBS-C/CIC class)</i> Continue with existing PA Criteria.	NO

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	ND- Mounjaro® NI-Ozempic®, Rybelsus®, Trulicity®	<u>DPP-IV Inhibitors</u> : Therapeutic alternatives. Must have one single ingredient agent. <u>GLP-1 & Combinations</u> : Therapeutic alternatives. Must have one single ingredient agent. Must have one agent with cardiovascular benefit.	NO
HYPOGLYCEMICS, INSULINS	NI-Lyumjev®	Class effect for each group. Must have one from each. (Human R, N, Rapid-acting, Long-Acting, Rapid/Intermediate, Reg/Intermediate Combos). Must have U-500 pen, do not add U-500 vial.	NO
IDIOPATHIC PULMONARY FIBROSIS	Class review- Esbriet®, Ofev®	Therapeutic alternatives. Continue with existing PA criteria. <i>*This class was previously a green category and brought back to the Board for a full review of all available agents.</i>	NO
UTERINE DISORDER TREATMENTS	NI- Myfembree®	Therapeutic alternatives.	NO

The Board reviewed the **blue category** in advance of the meeting. Kathy from Magellan reported on new doses and discontinued items in this category, as well as guideline updates. This category of drugs has no new clinically significant information since last review. Board recommendations for Group 2 (Blue category) from 2022 were retained. Blue category recommendations are as follows:

CLASS	2023 RECOMMENDATIONS	Grandfather
ANDROGENIC AGENTS, TOPICAL	Class effect.	NO
ANGIOTENSIN MODULATORS & COMBO	<u>Angiotensin Modulator Combinations</u> : Therapeutic alternatives. <u>Angiotensin II Receptor Blockers & Combinations</u> : Therapeutic alternatives. <i>*The Board requested that the Entresto® criteria be brought back for discussion at a future DUR meeting.</i> <u>ACE Inhibitors & Combinations</u> : Class effect. Do Not Add Tekturna® or Tekturna® HCT (due to aliskiren).	NO
ANTIANGINAL/ANTI-ISCHEMIC AGENTS	May add with PA criteria.	NO
ANTICOAGULANTS	Must have one LMWH, warfarin, Eliquis®, and Xarelto®.	NO
ANTIEMETIC AGENTS	Must have one 5-HT3 agent and one metoclopramide product. Continue with existing PA criteria.	NO
ANTIHYPERURICEMICS	Must have allopurinol and a single ingredient colchicine product. Continue with existing PA criteria.	NO
BETA-BLOCKERS	Must have metoprolol ER and carvedilol in some form. All other single ingredient agents have a class effect. Do not add combo agents containing diuretics-not first line agents and issues of concern with thiazides.	NO
BILE SALTS	Must have one ursodiol.	NO
CALCIUM CHANNEL BLOCKERS (DHP & non-DHP) and COMBOS	Must have a long-acting diltiazem and a long-acting verapamil. Must have amlodipine. All others are class effect.	NO
ERYTHROPOIESIS STIMULATING AGENTS-HEMATOPOIETIC AGENTS	Therapeutic alternatives.	NO

ESTROGEN: ORAL, TRANSDERMAL, & VAGINAL	<u>ORAL/TRANSDERMAL</u> : Class effect. Must have one topical and one oral. <u>VAGINAL</u> : Therapeutic alternatives.	NO
GLUCAGON AGENTS	Therapeutic alternatives.	NO
GROWTH HORMONE	Therapeutic alternatives.	NO
HAE TREATMENT	Therapeutic alternatives. Must include one on-demand treatment and one prophylactic treatment. Continue with existing PA criteria.	NO
HYPOGLYCEMICS: ALPHA GLUCOSIDASE INHIBITORS	Class effect.	NO
HYPOGLYCEMICS: MEGLITINIDES	Class effect.	NO
HYPOGLYCEMICS: METFORMINS	Must have metformin IR. Class effect for others.	NO
HYPOGLYCEMICS, SGLT2	Must have one agent with cardiovascular disease benefit. All others class effect. <i>*Criteria removed at the July 2022 DUR Board meeting.</i>	NO
HYPOGLYCEMICS: SULFONYLUREAS	Class effect.	NO
HYPOGLYCEMICS: TZDs	Class effect. <i>*Criteria removed at the September 2022 DUR Board meeting.</i>	NO
LIPOTROPICS, OTHERS	Must have gemfibrozil and one fenofibrate.	NO
LIPOTROPICS: STATINS	Must have 1 high potency agent, must have ezetimibe.	NO
PAH AGENTS: ORAL AND INHALED	Must have one ERA and one PDE-5. Retain GF & existing PA criteria.	YES
PANCREATIC ENZYMES	Class effect with patients being grandfathered on current treatment.	YES
PHOSPHATE BINDERS	Class effect.	NO
PLATELET AGGREGATION INHIBITORS	Must have immediate release aspirin. Must have one of prasugrel, clopidogrel, ticagrelor, or vorapaxar. Class effect for other agents. Grandfathered	YES
POTASSIUM BINDERS	Therapeutic alternatives.	NO
PROGESTINS FOR CACHEXIA	Class effect.	NO
PROTON PUMP INHIBITORS/H. PYLORI AGENTS	Class effect.	NO
ULCERATIVE COLITIS AGENTS	Class effect. Must have more than one route.	NO

One **green category** was not reviewed as all chemical entities are preferred at this time.

Class
PITUITARY SUPPRESSIVE AGENTS, LHRH

Meeting adjourned at 2:09p.m.

The next PDL meeting will be April 26, 2023, in this same format. Additional information will be posted by the Department.